Hypogonadism and Fertility Preservation - Clomiphene for Secondary Hypogonadism
Updated: Sep 28
How an inexpensive tablet can restart the signal without silencing sperm production
A carefully selected option for men whose testes can still respond and whose future family plans deserve a seat at the consultation table
Clomiphene works upstream through the brain and pituitary; gonadotrophins act closer to the testes. Both depend on choosing the right biological problem.
The short answer In selected men with genuine secondary or functional hypogonadism, clomiphene citrate can raise the body’s own testosterone while maintaining the hormonal signals needed for sperm production. It is oral, usually inexpensive and often well tolerated. It is also off label in men, does not work when the testes or the hypothalamic pituitary pathway cannot respond, and should follow a proper diagnostic assessment rather than a lonely low testosterone result.
The fertility question belongs at the beginning
A younger man arrives with tiredness, reduced libido, poorer concentration and two convincingly low morning testosterone results. Testosterone replacement seems an obvious answer. Yet there is one question that can change the entire prescription: might he want children now, or later?
External testosterone can improve androgen levels, but the brain interprets the incoming hormone as a signal that the system has enough. GnRH falls; luteinising hormone and follicle stimulating hormone fall; intratesticular testosterone falls; sperm production may slow markedly or stop. The blood test can look handsomely repaired while the fertility machinery has quietly taken annual leave.
This is why major guidelines advise against starting testosterone in men planning fertility. It is also why preserving fertility is not a small-print discussion to have after treatment begins. It belongs near the top of the page.
What secondary hypogonadism actually means
Testosterone production is governed by a three-level conversation. The hypothalamus releases gonadotrophin releasing hormone. The pituitary responds with LH and FSH. LH asks Leydig cells in the testes to make testosterone; FSH works with high local testosterone inside the testes to support Sertoli cells and sperm production.
In primary hypogonadism, the testes are the main site of failure. LH and FSH are usually high because the pituitary is already shouting. Turning up that same signal with clomiphene rarely helps.
In secondary or hypogonadotropic hypogonadism, testosterone is low while LH and FSH are low or inappropriately normal. The message from above is too quiet. Sometimes this reflects organic disease of the hypothalamus or pituitary. Sometimes the wiring is intact but suppressed by obesity, systemic illness, undernutrition, excessive exercise, obstructive sleep apnoea or medicines such as opioids and glucocorticoids. The latter is often called functional hypogonadism and remains a diagnosis of exclusion.
Before clomiphene the detective work
Clomiphene is an elegant treatment only after the diagnosis is equally elegant. Symptoms must fit, testosterone must be unequivocally and repeatedly low on properly timed morning samples, and the pattern of LH and FSH must support a central rather than testicular problem. Free testosterone can help when sex hormone binding globulin makes total testosterone difficult to interpret.
The assessment usually includes prolactin, medication and substance history, weight and metabolic health, sleep, systemic illness and other pituitary clues. Iron studies and additional pituitary hormones may be appropriate. Headache, visual disturbance, raised prolactin, other pituitary hormone deficits or severe secondary hypogonadism should prompt pituitary imaging. Not every man with a borderline result needs an MRI; equally, a tablet should never be used to place a small rug over a pituitary tumour.
Reversible causes deserve treatment in their own right. Better sleep, weight reduction, recovery from illness or reviewing a suppressive medicine may allow the axis to recover and improve health far beyond a testosterone number. Clomiphene should support that work when appropriate, not impersonate it.
How clomiphene restarts the conversation
Clomiphene citrate is a selective oestrogen receptor modulator. Men make oestradiol too, mainly by converting testosterone through aromatase, and oestradiol helps tell the hypothalamus and pituitary when enough sex hormone is circulating. Clomiphene partially blocks that feedback signal at the brain and pituitary.
The control room responds as if the hormonal volume is lower than it really is. GnRH signalling increases; LH and FSH rise; the testes are encouraged to produce testosterone and continue supporting spermatogenesis. Clomiphene does not deliver testosterone in a parcel. It asks the patient’s own axis to make more.
That distinction explains both its attraction and its limit. The upstream pathway must be capable of answering, and the testes must have useful reserve. In the right patient it is physiology with a gentle nudge. In the wrong patient it is pressing a doorbell whose wires are not connected.
What the evidence can honestly say
The evidence base is encouraging but smaller and less uniform than the evidence for conventional testosterone replacement. A 2022 systematic review included 19 studies and 1,642 men. Across the studies, clomiphene increased total and free testosterone as well as LH and FSH; commonly used symptom scores often improved. Reported adverse effects were generally uncommon, and no serious treatment related events were reported in the included cohorts. Most studies, however, were observational, follow up varied and symptom measurement was inconsistent.
A newer meta analysis of 10 randomised trials involving 819 men assessed clomiphene or enclomiphene. Selective oestrogen receptor modulator treatment increased testosterone, LH and FSH compared with placebo, while total testosterone was broadly comparable with testosterone gel. The trial evidence for sperm outcomes, symptoms and long term safety was less decisive, with important heterogeneity and some low certainty comparisons.
One short randomised study of 282 men who wished to preserve fertility compared oral clomiphene, hCG injections and the combination. Testosterone and symptom scores improved in all three groups over three months, with no meaningful difference in final testosterone between the groups. That study included authors from King’s College Hospital and helps explain why this inexpensive oral option has remained clinically interesting. It does not prove equal fertility or pregnancy outcomes, and three months is not a long marriage with any medicine.
So the defensible message is not that clomiphene is a universal, risk free substitute for testosterone. It is that clomiphene often raises endogenous testosterone and usually preserves the hormonal environment for fertility in appropriately selected men. Preserving the pathway is not the same as guaranteeing a normal semen analysis, conception or live birth.
Three treatments and three different instructions
These therapies can all raise circulating testosterone, but they enter the pathway at different doors. The choice depends on where the biological problem sits and whether fertility is an immediate objective or a future priority.
Clomiphene Citrate | hCG +/- FSH | Testosterone | |
What it does | Reduces oestrogen feedback so the pituitary releases more LH and FSH | hCG acts like LH at the testis; FSH may be added to drive spermatogenesis | Supplies testosterone directly from outside the body |
Route | Oral tablet | Repeated injections, often several times each week | Gel, injection or another licensed formulation |
Needs an intact axis | Yes. Pituitary response and testicular reserve are essential | Bypasses the pituitary but still needs responsive testes | No pituitary or testicular response is required to raise blood testosterone |
Effect on fertility pathway | Usually maintains or increases LH and FSH and is fertility sparing | Designed to support testicular testosterone and sperm production | Suppresses LH and FSH and can markedly impair sperm production |
Best fit | Selected functional or secondary hypogonadism with intact anatomy and a wish to preserve fertility | Classical or organic secondary hypogonadism; active paternity goal; inadequate response to an upstream strategy | Confirmed hypogonadism when fertility is not required and standard replacement is appropriate |
Evidence and status | Off label in men; encouraging trials and observational evidence, but limited long term fertility outcomes | Guideline standard for fertility induction in secondary hypogonadism; specialist regimens | Licensed and guideline established for appropriate hypogonadism |
Practical trade off | Usually inexpensive and convenient; response varies and monitoring remains necessary | More direct and dependable when the pituitary cannot respond; injections and cost are greater | Effective androgen replacement; fertility suppression is the crucial trade off |
Who is a good candidate
A good candidate is defined by biology, symptoms and priorities rather than age alone. The most persuasive pattern is:
Meaningful symptoms alongside consistently low morning testosterone on at least two occasions.
Low or inappropriately normal LH and FSH, suggesting that the pituitary signal could be amplified.
No evidence of primary testicular failure and reasonable testicular reserve.
No untreated structural pituitary cause, important hyperprolactinaemia or other endocrine disorder requiring specific treatment.
A present or future wish to preserve fertility, or a strong preference to maintain endogenous testicular function.
Readiness to address reversible contributors and attend biochemical and clinical follow up.
When clomiphene is the wrong key
Clomiphene is unlikely to help primary testicular failure, where LH and FSH are already high. It is also unreliable when the hypothalamus or pituitary is organically unable to respond, including some cases of severe congenital or acquired hypogonadotropic hypogonadism. Those men may need gonadotrophins for fertility induction and standard hormone replacement when fertility is not being pursued.
Men with severe oligospermia or azoospermia who are actively trying to conceive should not lose valuable time to an empirical tablet without semen analysis and specialist reproductive assessment. Fertility is a couple level outcome, and the microscope is less easily charmed than the serum testosterone result.
A history of venous thromboembolism or thrombophilia, significant liver disease, unexplained visual symptoms or relevant contraindications requires particular caution and often an alternative. Individual risk assessment matters because male use is off label and robust long term safety data remain limited.
Monitoring is part of the treatment
Specialist prescribing normally begins with baseline symptoms, examination and relevant hormone results, followed by review after treatment has had time to act. Dosing is individualised; this article deliberately avoids turning a specialist consultation into a recipe card.
Follow up commonly considers total testosterone, LH, FSH and oestradiol, with full blood count or haematocrit, liver tests and prostate assessment when clinically appropriate. The most important laboratory measure is the one connected to the patient’s goal: if fertility matters, a baseline and follow up semen analysis can be more informative than admiring testosterone in isolation.
Treatment should also earn its place. A higher testosterone result without meaningful clinical benefit deserves reassessment. So does an unexpectedly poor biochemical response, which may reveal inadequate testicular reserve, poor adherence, a missed diagnosis or a pathway that cannot be stimulated.
Side effects without melodrama or amnesia
Most published male cohorts describe clomiphene as generally well tolerated, and large observational series report side effects in a minority of patients. Possible effects include headache, dizziness, nausea, acne, breast tenderness, irritability or mood change and a rise in oestradiol. Testosterone and haematocrit still require sensible monitoring; an oral tablet has not signed a treaty with physiology.
Visual disturbance is uncommon but important. New blurring, flashes, spots, double vision or eye pain should prompt stopping the medicine and urgent clinical advice. Venous thromboembolism has been reported rarely and is a theoretical concern with selective oestrogen receptor modulators; new unilateral leg swelling, chest pain or unexplained breathlessness requires urgent assessment.
The reassuring safety signal is therefore useful, but “generally well tolerated in selected and monitored men” is more honest. Rare events and long term outcomes are precisely where small studies are least able to reassure us.
Where gonadotrophins remain stronger
Gonadotrophin treatment is not simply injectable clomiphene. hCG acts directly on the LH receptor in the testis, and FSH can be added to stimulate Sertoli cells and sperm production. This makes gonadotrophins the guideline standard when a man with secondary hypogonadism seeks paternity, particularly when the pituitary cannot generate an adequate signal.
The advantages are biological directness and long clinical experience in fertility induction. The disadvantages are repeated injections, closer specialist supervision, cost and the patience required for spermatogenesis, which works on the scale of months rather than a hurried weekend.
Clomiphene can reach a similar immediate goal in some men—higher endogenous testosterone with the fertility pathway left open—but it does not make gonadotrophins redundant. It is most attractive when the upstream axis is intact, convenience matters and fertility preservation is important. Gonadotrophins become more compelling when fertility is active rather than hypothetical, the deficit is organic or severe, semen parameters are poor, or clomiphene fails.
The balanced conclusion
Clomiphene citrate sits in a useful space between doing nothing and replacing testosterone from outside. For a symptomatic man with confirmed secondary or functional hypogonadism, intact pituitary testicular function, no untreated structural cause and a wish to preserve fertility, it can be an intelligent, inexpensive oral option.
Its elegance lies in respecting the architecture of the axis: the brain still signals, the testes still produce testosterone and the machinery for sperm production is not deliberately switched off. Its safety lies less in calling it harmless than in choosing carefully, explaining the off label evidence and monitoring properly.
The right question is therefore not “Is clomiphene better than testosterone?” It is “Which signal has failed, what does this patient want to preserve, and which treatment solves that particular problem?” Endocrinology tends to reward such questions. It is fussy like that—but usually for good reason.
Questions worth bringing to a specialist consultation
Do my symptoms and two morning blood tests genuinely establish hypogonadism?
Do my LH and FSH results suggest primary or secondary hypogonadism?
Have prolactin, medicines, sleep, weight, systemic illness and pituitary red flags been assessed?
Should I have a semen analysis before any treatment?
Is clomiphene reasonable for my biology, and what result would count as success?
At what point would hCG with or without FSH be a better route?
Important Clomiphene use in men is off label. This article is educational and cannot replace individual assessment by an endocrinologist, andrologist or fertility specialist. Do not start, stop or alter hormone treatment without medical advice.
Evidence and further reading
Editorial note Evidence was reviewed through September 2026. The article distinguishes biochemical testosterone responses from proven fertility and pregnancy outcomes, because these are not interchangeable endpoints.
Comments